ASH News Daily - Sunday, December 11, 2011 - (Page C-7)

Sunday, December 11, 2011 ASH NewS DAily and students over 26; military and 25 and under are free The collection of the Museum of Contemporary Art San Diego (MCASD) includes more than 4,000 works created after 1950, representing a variety of media and genres: painting, sculpture, works on paper, photography, video, and installation. MCASD is known for collecting works by promising emerging artists and under-recognized, mid-career artists, as well as by major figures in international contemporary art. National Comedy Theatre 3717 India Street http://nationalcomedy.com Adults: $15 Open: Fri. and Sat.: 7:30 p.m. and 9:45 p.m. Sun.: 8:00 p.m. Admission: $12 students, seniors, and military; $10 college nights, Sundays and midnight shows Laughter is the best medicine! Enjoy a comical, family-friendly evening at San Diego’s premier improvisational comedy hotspot. The Old Globe 1363 Old Globe Way www.oldglobe.org What’s Playing: Dr. Seuss’ How the Grinch Stole Christmas Showtimes during conference: Page C–7 ® SAn diego trAvel guide Sights «« From Page C-6 Weekends at 11:00 a.m., 7:00 p.m., and 5:00 p.m.; Tues. at 10:30 a.m. and 7:00 p.m. Admission: Varies, see website. This Tony award-winning theater is California’s oldest professional theater and features both classic and contemporary productions. San Diego Museum of Art 1450 El Prado Open: Tues. through Sat. from 10:00 a.m. to 5:00 p.m.; Sun. from 12:00 noon to 5:00 p.m. Closed Mondays. »» SIGHTS Page C-14 Holiday of Lights at the Del Mar Fairgrounds 2260 Jimmy Durante Boulevard Del Mar www.holidayoflights.com Open: Sun. through Thurs. from 5:30 to 10:00 p.m. Fri. and Sat. from 5:30 to 10:30 p.m. Closed Monday, December 12. Admission: $14/vehicle, up to 5 people and $19/vehicle, 6 or more people View the largest animated drivethrough light show on the West Coast. Themes include Twelve Days of Christmas, Candy Cane Lane, Toyland, San Diego County Fair, and Del Mar Racetrack. The Junípero Serra Museum 2727 Presidio Drive www.sandiegohistory.org/serra_ museum.html Open: Weekends 10:00 a.m. to 5:00 p.m. Admission: $6 adults; $4 seniors, students, and military (ID required); $2 for children ages 6-17; and free for children under 6 A major symbol of the city, the museum stands atop the hill recognized as the site where California began. It was here that a Spanish Franciscan missionary, Father Junípero Serra, with a group of soldiers led by Gaspar de Portolá, established Alta California’s first mission and presidio (fort) in 1769. Legoland 1 Legoland Drive Carlsbad http://california.legoland.com Open: December 10 from 10:00 a.m. to 6:00 p.m. December 11 and 12 from 10:00 a.m. to 5:00 p.m. Closed December 13 and 14 Admission: Ages 3-12/60+ $59. Ages 13 and up $69. Enjoy the miniature Lego-block replicas of landmarks such as the Empire State Building, the Golden Gate Bridge, and the Lincoln Memorial, ride a rollercoaster, or admire the interactive attractions of one of only four Legolands in the world. Museum of Contemporary Art San Diego 1100 Kettner Boulevard www.mcasd.org Open: Thurs. through Tues. from 11:00 a.m. to 5:00 p.m., Third Tues. of the month from 11:00 a.m. to 7:00 p.m. Closed Wednesdays. Admission: $10 adults; $5 seniors Vosaroxin and Ara-C combination evaLuating Overall survival in Relapsed/refractory AML N OW ENROLLING! Pivotal Phase 3, randomized, controlled, double-blind, multinational clinical trial evaluating efficacy and safety of vosaroxin (VŌZ-ah-rox-in)—a first-in-class anticancer quinolone derivative (AQD)—plus cytarabine vs. placebo plus cytarabine for patients with first relapsed or refractory acute myeloid leukemia (AML). 90% power to detect a 40% improvement in overall survival. Innovative, adaptive trial design allows for a one-time sample size adjustment by the Data Safety Monitoring Board at the interim analysis to ensure adequate power across a broader range of clinically meaningful and statistically significant survival outcomes. Vosaroxin dose and schedule: 90 mg/m2 10-minute infusion or placebo on days 1 and 4; cytarabine (IDAC) 1 g/m2 given as a 2-hour IV infusion on days 1 through 5. Designed from results of a Phase 2 trial of the vosaroxin/cytarabine combination in 36 first relapsed [median CR1 duration of 7.3 months] and 33 primary refractory [median of 2 prior cycles (range of 1-6)] AML patients. For this Phase 2 trial, the median overall survival was 7.1 months, the combined complete remission rate was 28% (CR rate 25%), and the leukemia-free survival was 25 months. The 30-day and 60-day all-cause mortality was low at 3% and 9%, respectively. Infection-related toxicities were the most common Grade 3 or higher nonhematologic adverse events.1,2 VALOR Endpoints and Entry Criteria Primary endpoint Secondary endpoints Major entry criteria Overall survival CR rate Safety and tolerability At least 18 years of age ECOG performance status of 0-2 First relapse (CR duration between 90 days and 24 4 months) OR refractory (CR duration ≤90 days or refractory to 1 or 2 prior induction therapies) CR=complete remission by International Working Group (IWG) response criteria; ECOG=Eastern Cooperative Oncology Group. VAL VALOR Trial Design Consolidation (1-2 cycles) Study Arm First Relapsed or Refractory AML Vosaroxin + IDAC Induction (1-2 cycles) CR or CRp IDAC=intermediate-dose Ara-C; CR=complete remission; CRp=complete remission with incomplete platelet recovery; CRi=complete remission with incomplete recovery of platelets and neutrophils; PR=partial remission. If you treat AML, consider whether any of your patients are eligible y for enrollment in the VALOR trial. For more information, visit clini clinicaltrials.gov or www.valortrial.com, or contact Sunesis Clinical D Development at 888-71-VALOR or valortrial@sunesis.com. Smartphone users: take a picture of this image to visit the VALOR trial Website Reference 1. Roboz GJ, Lancet JE, Cripe LD, et a Results of a phase 2 pharmacokinetic/ al. pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Poster presented at: American Society of Clinical Oncology 2010 Annual Mee Meeting; June 4-8, 2010; Chicago, Illinois. Abstract 6526. 2. Data on file, Sunesis. Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard Suite 400 South San Francisco, CA 94080 Copyright © Sunesis Pharmaceuticals, Inc. 2010. Copyright © Sunesis Pharmaceuticals, Inc. 2011. All Rights Reserved. VOS-010-01 10/2011 Printed in USA 1:1 Randomization Survival Follow Up Control Arm Placebo + IDAC CRi, PR, or Treatment Failure  http://www.nationalcomedy.com http://www.holidayoflights.com http://www.oldglobe.org http://www.sandiegohistory.org/serra_museum.html http://california.legoland.com http://www.mcasd.org

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com